Zegbeh Jallah analyst CAPITAL ONE

Currently out of the existing stock ratings of Zegbeh Jallah, 167 are a BUY (96.53%), 5 are a HOLD (2.89%), 1 are a SELL (0.58%).

Zegbeh Jallah

Work Performance Price Targets & Ratings Chart

Analyst Zegbeh Jallah, currently employed at CAPITAL ONE, has had 40.07% of price targets met with an average potential upside of 40.79%, reached in 340 days on average. Previously, Zegbeh Jallah worked at ROTH MKM.

Zegbeh Jallah has documented 324 price targets and ratings displayed on 27 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on EYPT, Eyepoint Pharmaceuticals at 25-Oct-2024.

Wall Street Analyst Zegbeh Jallah

Analyst best performing recommendations are on OCGN (OCUGEN).
The best stock recommendation documented was for OCGN (OCUGEN) on 2/3/2021. The price target of $8 was fulfilled within 5 days with a profit of $5.19 (184.7%), with a performance score of 369.4.

Average potential price target upside

AGTC Applied Genetic ARVN Arvinas CLSD Clearside Biomedical DARE Dare Bioscience ENTA Enanta Pharmaceuticals GLYC GlycoMimetics HARP Harpoon Therapeutics IDYA Ideaya Biosciences JNCE Jounce Therapeutics KALV Kalvista Pharmaceuticals KOD Kodiak Sciences LIFE aTyr Pharma OCGN Ocugen RZLT Rezolute TPTX Turning Point Therapeutics RAPT RAPT Therapeutics IVA Inventiva Sa XFOR X4 Pharmaceuticals IMUX Immunic SYRS Syros Pharmaceuticals AIMT Aimmune Therapeutics OTLK OUTLOOK THERAPEUTICS INC AG First Majestic Silver Corp AI C3 Ai CLS Celestica GL Globe Life EYPT Eyepoint Pharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 11-Feb-2015

4 years 26 days ago
(25-Oct-2022)

2/13 (15.38%)

$13.99 (348.88%)

660

Hold Since 25-Oct-2022

$0.4

4 years 26 days ago
(25-Oct-2022)

1/1 (100%)

$0.01 (2.56%)

2

Hold Since 24-Oct-2022

$0.34

4 years 27 days ago
(24-Oct-2022)

0/5 (0%)

$-0.05 (-12.82%)

Buy Since 09-Feb-2017

$9

4 years 27 days ago
(24-Oct-2022)

0/3 (0%)

$7.17 (391.80%)

Buy Since 11-Nov-2020

$11

4 years 1 months 22 days ago
(29-Sep-2022)

0/2 (0%)

$6.72 (157.01%)

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Zegbeh Jallah?

On 2019
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?